News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Relief Therapeutics reports positive results from RLF-OD032 proof-of-concept clinical study for Phenylketonuria, showing bioequivalence with KUVAN(R) in managing PKU. RLF-OD032 aims to offer a patient-friendly, portable solution for PKU treatment -
-
-
-
-
COMMUNIQUÉ DE PRESSE
Rektron Schedules Annual General and Special Meeting of Shareholders in Response to Shareholder Requisition
Rektron Group Inc. announces annual general and special meeting in response to Concerned Shareholders' requisition for changes in the Board of Directors. Shareholders to receive details via management circular. The Company specializes in global commodity trading with a focus on energy and metals products